Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Net Income towards Common Stockholders: 2023-2024

Historic Net Income towards Common Stockholders for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $1.7 billion.

  • Inhibrx Biosciences' Net Income towards Common Stockholders rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.44%. This contributed to the annual value of $1.7 billion for FY2024, which is 803.96% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Net Income towards Common Stockholders stood at $1.7 billion for FY2024, which was up 803.96% from -$239.7 million recorded in FY2023.
  • Inhibrx Biosciences' 5-year Net Income towards Common Stockholders high stood at $1.7 billion for FY2024, and its period low was -$239.7 million during FY2023.
  • Moreover, its 2-year median value for Net Income towards Common Stockholders was $723.9 million (2023), whereas its average is $723.9 million.
  • Data for Inhibrx Biosciences' Net Income towards Common Stockholders shows a peak YoY skyrocketed of 803.96% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Inhibrx Biosciences' Net Income towards Common Stockholders stood at -$239.7 million in 2023, then surged by 803.96% to $1.7 billion in 2024.